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2Abstract: Medicated shellac nanofibers providing colon-specific sustained release41
were fabricated using coaxial electrospinning. A mixed solution of 75% (w/v) shellac42
and 15% (w/v) ferulic acid (FA) in ethanol was used as the core fluid, and a mixture43
of ethanol and N,N-dimethylformamide (8/10 v/v) as the shell. The presence of the44
shell fluid was required to prevent frequent clogging of the spinneret. The diameters45
of the fibers (D) can be manipulated by varying the ratio of shell to core flow rates (F),46
according to the equation D=0.52F-0.19. Scanning electron microscopy images47
revealed that fibers prepared with F values of 0.1 and 0.25 had linear morphologies48
with smooth surfaces, but when the shell fluid flow rate was increased to 0.5 the fiber49
integrity was compromised. FA was found to be amorphously distributed in the fibers50
on the basis of X-ray diffraction and differential scanning calorimetry results. This can51
be attributed to good compatibility between the drug and carrier: IR spectra indicated52
the presence of hydrogen bonds between the two. In vitro dissolution tests53
demonstrated that there was minimal FA release at pH 2.0, and sustained release in a54
neutral dissolution medium. The latter occurred through an erosion mechanism.55
During the dissolution processes, the shellac fibers were gradually converted into56
nanoparticles as the FA was freed into solution, and ultimately completely dissolved.57
58
Keywords: Medicated nanofibers; Colon-targeted release; Coaxial electrospinning;59
Erosion mechanism; Shellac60
61
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31. Introduction63
Over the last decades, a wide variety of different materials have been considered64
as carriers for drug delivery systems. These include both synthetic polymers and65
macromolecules extracted from natural products, such as proteins and polysaccharides66
(Allen and Cullis, 2004; Liu et al., 2008). Shellac, a resin secreted by the female lac67
beetle, is one material to have attracted much attention for biomedical applications68
(Limmatvapirat et al., 2008; Limmatvapirat et al., 2007). These polymers have been69
processed by a broad gamut of technologies with the aim of preparing advanced drug70
delivery systems (DDS), with nanotechnologies being particularly popular (Farokhzad,71
2008; Hubbell and Chikoti, 2012). Because of the convenience and high patient72
compliance associated with oral administration, nanotechnology has been widely73
explored in this content (Pouton and Porter, 2008).74
75
Nanoscale products have shown particular potential for the effective oral delivery of76
poorly water-soluble active ingredients. This is because nanoscale products have large77
surface-area-to-volume ratios and thus, if solid solutions (or suspensions) of a drug in78
a carrier can be prepared, it is facile to accelerate dissolution rate and enhance79
solubility (Merisko-Liversidge and Liversidge, 2011). There are a range of80
approaches which can be used to prepare nanoscale DDS, which can broadly be81
classified as “top down” or “bottom up”. Of the former, electrospinning has proven82
popular for generating medicated nanofibers; these one-dimensional systems have83
been widely studied for application as a broad range of DDS, including for oral84
4administration. Importantly, electrospinning has the ability to be moved to large-scale85
production (Vrbata et al., 2014; Nagy et al., 2015). Medicated nanofibers are86
fabricated from a mixed solution or melt comprising a carrier polymer and the desired87
active ingredient; these are most commonly processed using single fluid88
electrospinning (Paaver et al., 2015; Balogh et al., 2015).89
Around one hundred polymers have been successfully electrospun into fibers90
(Sun et al., 2014). Among these, more than ten are frequently spun with active91
pharmaceutical ingredients to create medicated fibers – for instance,92
poly(vinylpyrrolidone), ethyl cellulose, and chitosan (Yu et al., 2013). In general,93
natural polymers have been more widely studied than synthetic materials for oral drug94
delivery (Sridhar et al., 2015). Proteins including collagen (Zhang et al., 2013), silk95
fibroin (Dinis et al., 2014), keratin (Mogosanu et al., 2014; Edwards et al., 2015),96
gelatin (Baigvera et al., 2014), and polysaccharides such as chitosan (Lin et al., 2013),97
alginate (Ma et al., 2012), and cellulose and its derivatives (Kai et al., 2015) have all98
been electrospun and explored for drug delivery systems.99
Colon-targeted drug delivery is attractive not only for local delivery to treat100
diseases of the colon, but also for improving the bioavailability of poorly101
water-soluble drugs as a result of the long retention time and high colonic surface area102
(Vats and Pathak, 2013). Shellac is insoluble in the stomach, and thus has proved to103
be useful as a drug carrier for colon-targeted delivery in traditional formulation104
approaches (Ravi et al., 2008). Shellac-coated tablets are ubiquitous in the pharmacy,105
and new developments in this area are still being explored (Rachmawati et al., 2012):106
5in one recent example, Henning et al. investigated the use of shellac to coat107
liquid-filled pectinate capsules and target delivery to the colon (Henning et al., 2012).108
In this work, for the first time, colon-targeting shellac nanofibers loaded with the109
anti-oxidant phytochemical ferulic acid were created using a coaxial electrospinning110
process. The sheath fluid comprised a mixture of ethanol and dimethylformamide,111
while the core contained the polymer and active ingredient. The influence of the shell112
solvent flow rate on fiber formation and the drug release mechanism were studied.113
114
2. Materials and methods115
2.1. Materials116
Shellac (95% purity, wax free) was obtained from the Shanghai Wanjiang117
Bio-Technology Co., Ltd. (Shanghai, China). Ferulic Acid (FA, 98% purity, batch no.118
201407116) was purchased from the Shanghai Tongtian Bio-Technology Co., Ltd.119
(Shanghai, China). Anhydrous ethanol and N,N-dimethylformamide (DMF) were120
provided by the Shanghai Guangjia Chemicals Co., Ltd. (Shanghai, China). All121
chemicals used were analytical grade and water was doubly distilled before use.122
2.2. Preparation of working fluids and electrospinning123
A solvent mixture consisting of 80% ethanol and 20% DMF (v/v) was used as the124
shell working fluid. A mixed solution composed of 75% (w/v) of shellac and 15%125
(w/v) FA in ethanol comprised the core fluid. The electrospinning system was formed126
from a ZDF-2000 power supply (Shanghai Sute Electrical Co., Ltd., Shanghai, China),127
two KDS 100 syringe pumps (Cole-Parmer®, Vernon Hills, IL, USA), a homemade128
6concentric spinneret, and a flat piece of cardboard wrapped with aluminum foil used129
as the fiber collector. Four different types of fibers were prepared with a fixed core130
fluid flow rate of 2.0 mL/h and a varied shell fluid flow rate (Table 1). The applied131
voltage and spinneret-to-collector distance were fixed at 12 kV and 15 cm,132
respectively. The electrospinning processes was recorded using a digital camera133
(PowerShot A490, Canon, Tokyo, Japan).134
Table 1. Details of the electrospinning processes and resultant fibers.135
136
a The shell fluid consisted of 80% (v/v) ethanol and 20% (v/v) DMF.137
b The core fluid consisted of 75% (w/v) shellac and 15% (w/v) of FA in ethanol.138
139
2.3. Morphology140
The morphology of the fibers was assessed with a QuantaFEG450 scanning141
electron microscope (SEM; FEI Corporation, Hillsboro, OR, USA). Samples were142
subjected to gold sputter-coating under a vacuum to endow them with electrical143
conductivity prior to measurement. The sizes of the fibers were estimated by144
measuring them in SEM images at ≥ 100 points, using the ImageJ software (National 145
Institute of Heath, Bethesda, MD, USA). Cross-section fiber samples were prepared146
by immersing them into liquid nitrogen for 30 minutes and breaking the mats147
manually.148
2.4. Physical form and compatibility of components149
Both X-ray diffraction (XRD) and differential scanning calorimetry (DSC) were150
carried out to investigate the physical form of the components in the fibers. XRD151
No. Process
Fluid flow rate (mL/h)
Morphology Size (μm) 
Shell a Core b
F1 Single fluid 0 2.0 Linear fibers 1.27 ± 0.31
F2 Coaxial 0.2 2.0 Linear fibers 0.87 ± 0.14
F3 Coaxial 0.5 2.0 Linear fibers 0.64 ± 0.15
F4 Coaxial 1.0 2.0 complicated --
7analyses were performed using a D/Max-BR instrument (Rigaku, Tokyo, Japan) with152
Cu Kα radiation. Measurements were recorded over the 2θ range 5° to 60° at 40 mV 153
and 30 mA. DSC was conducted using an MDSC 2910 differential scanning154
calorimeter (TA Instruments Co., New Castle, DE, USA). Samples were heated at a155
rate of 10 °C/min from 20 °C to 250 °C under a flow of nitrogen (40 mL/min).156
Fourier transform infrared (FTIR) spectra were recorded on a Spectrum 100157
FTIR spectrometer (PerkinElmer, Waltham, MA, USA) over the range 500 cm-1 to158
4000 cm-1 at a resolution of 2 cm-1.159
2.5. In vitro dissolution tests160
In accordance with the Chinese Pharmacopoeia (2010 Ed.), in vitro dissolution tests161
were conducted using a paddle method on a RCZ-8A dissolution apparatus (Shanghai162
Huanghai Medicine Checking Instrument Co., Ltd., Shanghai, China). 0.18 g of the163
medicated fibers F2 and F3 (equivalent to 30 mg of FA) were first placed in 900 mL164
of 0.01 N HCl solution for 2h, and later transferred to 900 mL of phosphate buffered165
saline (PBS, pH 7.0, 0.1 mol/L) for the remainder of the experiment. The temperature166
of the dissolution media was maintained at 37 ± 1 °C and the paddle rotation speed at167
50 rpm. At pre-determined time intervals, 5.0 mL samples were withdrawn and168
replaced with fresh medium to maintain a constant volume. After filtration and a169
suitable dilution with PBS, samples were analyzed at λmax = 322 nm using a Lambda170
950 UV/vir/NIR spectrophotometer (PerkinElmer, Waltham, MA, USA). The171
cumulative amount of FA released at each time point was back-calculated from the172
data obtained against a predetermined calibration curve. Experiments were performed173
six times, and the results are reported as mean ± S.D.174
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3. Results and discussion176
3.1. Nanofiber design strategy177
A schematic explaining the design rationale for the medicated shellac nanofibers178
prepared in this work is shown in Fig. 1. The concentric spinneret is used as a179
template to manipulate the two fluids of the electrospinning process. The shell solvent180
will aid the achievement of a continuous spinning process, ameliorating problems181
with spinneret clogging and resulting in narrower nanofibers.182
The drug-loaded shellac nanofibers can easily be converted into a suitable dosage183
form for oral administration, for example by incorporation into a capsule. Because184
shellac is insoluble in acidic conditions, the fibers can protect the loaded active185
ingredient and hinder release in the stomach. Subsequently, as the pH value of the186
digestive tract gradually increases, the shellac will absorb water, swell and dissolve,187
freeing the drug into solution.188
Fig. 1.189
3.2. Electrospinning190
Initially, single-fluid electrospinning was attempted (using the coaxial spinneret, with191
the flow rate of the shell solvent set to 0 mL/h). The results of this process are192
depicted in Fig. 2a. Although nanofibers could be produced, a semi-solid substance193
was found to gradually accumulate on the spinneret, causing clogging (Fig. 2a, inset)194
and halting the electrospinning process. This blockage had periodically to be195
manually removed to permit spinning to continue. In contrast, in the modified coaxial196
9process electrospinning could be run continuously without any user intervention (see197
Fig. 2b). A compound core-shell Taylor cone could be clearly observed (Fig. 2b,198
inset).199
Fig. 2.200
3.3. Morphologies of the raw materials and fibers201
Ferulic acid (FA) appears by SEM to be a crystalline powder (Fig. 3a) with a202
slight yellow color (Fig. 3a inset), whose particles are somewhat less than 50 µm in203
size. Shellac exists as flakes with smooth surfaces, as shown by the SEM image in Fig.204
3b. These have a slight pinkish color (Fig. 3b inset).205
After electrospinning, nanoscale fibers are produced: SEM images of these are206
given in Fig. 3c to 3e. Fibers F1 to F3, produced under shell-to-core fluid flow rate207
ratios (F) of 0, 0.1 and 0.25 respectively, have linear morphologies without any208
“beads-on-a-string” phenomena observed. In contrast, when the shell-to-core fluid209
flow rate ratio was further increased to 0.5, the products exhibited varied210
morphologies, as illustrated in Fig. 3f. Linear fibers can be found, but so can fibers211
with beads-on-a-string morphology, together with many clumps and droplets. The212
excessive shell solvent flow rate used here clearly caused detrimental effects to the213
products. Thus, a suitable flow rate ratio is key for creating nanofibers with high214
quality in this setting.215
Considering F1 – F3, as the value of F increases, the average diameters (D) of216
the nanofibers decrease correspondingly (Fig. 3g). Attempts were made to fit the size217
data using a linear equation (D1, F1 and R1) and exponential equation (D2, F2 and R2).218
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These gave D1=1.09-1.87F1 (R1=0.9118) and D2=0.52F2-0.19 (R2=0.9927) respectively219
(Fig. 3g): since R2 > R1, an exponential relationship seems more appropriate. Similar220
results have previously been reported when surfactant (Triton X-100) or electrolyte221
(sodium dodecylbenzene sulfonate) solutions were used as shell fluids in coaxial222
processes to prepare polyacrylonitrile fibers (Yu et al., 2012a; Yu et al., 2012b).223
During the coaxial electrospinning processes, the shell solvent system performs224
two roles. First, it lubricates the core shellac solution. This helps to prevent the225
formation of semi-solid substances and clogging of the spinneret. Second, the shell226
solvent surrounds the sticky core solution not only during the formation of the227
compound Taylor cone, but also in the straight fluid jets and into the bending and228
whipping regions. It thus helps to keep the core jet in a fluid state for a longer time,229
allowing it to experience extended electrical drawing. One concern about this230
double-fluid process, however, is whether the shell solvent causes any solid phase231
separation to occur. Hence, the cross-sections of F2 and F3 were investigated by SEM232
(insets of Fig. 3d and 3e, respectively). The fiber cross-sections, just as their surfaces,233
are very smooth without any visible particles or any other signs of phase separation.234
Fig. 3.235
3.4. Physical form and component compatibility236
The rapid drying which arises during electrospinning (often on a time scale of237
10-2 s), has rendered it a popular method to generate amorphous dosage forms of238
poorly water-soluble drugs (Nagy et al., 2015). In order to probe the physical form of239
the drug in the nanofibers prepared here, we employed X-ray diffraction (XRD) and240
11
differential scanning calorimetry (DSC). Fig. 4a depicts XRD patterns of the raw241
materials and fibers. The existence of many distinctive Bragg reflections in the FA242
pattern is consistent with the SEM data (Fig. 3a), and clearly demonstrates that it243
exists as a crystalline material. In contrast, the pattern for shellac contains only a244
diffuse halo, as expected since it is known to be an amorphous material. Considering245
the XRD patterns of the fibers, none of the characteristic FA reflections are visible for246
F2 or F3, showing that FA exists in an amorphous state in the fibers, having lost its247
original crystalline form.248
The DSC data are entirely consistent with this. The single endothermic response249
at 174 °C in the DSC thermogram of FA (Fig. 4b) corresponds to melting, confirming250
the pure FA powder to be a crystalline material. There are no melting events in the251
DSC curves of shellac, F2, or F3, concurring with the XRD data and proving them to252
be amorphous.253
IR spectra are given in Fig. 4c and chemical structures of the fiber components in254
Fig. 4c (FA) and 4d (shellac). Both FA and shellac contain–OH and –C=O groups,255
suggesting that hydrogen bonds can form between them. The characteristic peaks of256
FA at 1689, 1663 and 1619 cm-1 result from the vibration of –C=O groups in the257
crystal lattice. These vibrations are merged into a single peak at 1698 cm-1 in the258
spectra of F2 and F3. In addition, many peaks in the fingerprint region of the FA259
spectrum have disappeared in the fibers’ spectra. These phenomena taken together260
verify that FA molecules form composites with shellac through hydrogen bonds,261
which should improve the components’ compatibility and thereby fiber stability.262
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Fig. 4.263
3.5. In vitro dissolution tests and drug release mechanism264
The results of in vitro dissolution tests on F2 and F3 are exhibited in Fig. 5a. As a265
result of shellac’s insolubility in acidic conditions, only a small percentage of FA was266
released into the dissolution medium during the first two hours at pH 2.0. As is clear267
from the inset of Fig. 5a, only 8.2% and 9.3% of the embedded FA was released from268
F2 and F3, respectively. Subsequently, the fibers provided very similar sustained269
release profiles when they were transferred into the neutral PBS dissolution medium.270
The FA release profiles from nanofibers F2 and F3 was analyzed according to271
the Peppas equation (Peppas, 1985):272
Q=kt n273
where Q is the drug accumulative release percentage, t is the release time, k is a rate274
constant, and n is the release exponent, through which the drug release mechanism275
can be elucidated. The regressed equations for F2 and F3 between 2 and 8 hours of276
dissolution are Q2=12.9 t20.95 (R2=0.9840) and Q3=14.4t30.93 (R3=0.9696), respectively.277
The release exponents are 0.95 and 0.93 respectively: slightly larger than 0.89,278
suggesting that FA release was mainly controlled by the erosion of the polymer279
matrix.280
Given this, one would expect that the shellac must dissolve faster than the281
encapsulated FA, and thus the dissolution medium should be almost transparent when282
the FA release approached 100%. However, in fact the dissolution media were still283
cloudy even after 8 h. To understand this, the F2 dissolution experiments were284
13
repeated, and the fiber mats recovered after various immersion times. The mats were285
dried under vacuum before being imaged by SEM. The resultant images are given in286
Fig. 5b to 5g.287
Fig. 5.288
It can be seen that the fibers are curved and broken in places after immersion in289
the dissolution media. Their diameters seem to rise, and increasing numbers of290
nanoparticles appear as dissolution progresses. This is believed to be a result of291
changes in the shellac molecular conformations as the FA molecules are freed into292
solution.293
A schematic diagram explaining the proposed mechanism of drug release is294
presented in Fig. 6. When the nanofibers are transferred into the neutral PBS buffer295
solution, shellac molecules can absorb water and cause the fibers to swell. As a result,296
the compact structures of the nanofibers gradually expand and unfold. In the297
medicated fibers, FA molecules are associated with shellac molecules through298
hydrogen bonds. The fiber swelling and concomitant unfolding of shellac molecules299
permit the FA molecules to be freed into solution. During this time, the physical300
entanglements of shellac (marked “A” in Fig. 6) are thought to undergo minimal301
changes. However, the departure of FA molecules will promote the formation of302
hydrogen bonds between nearby –OH and –C=O groups within shellac molecules303
(“B” and “C” in Fig. 6), which in turn result in their crimping. Therefore, the erosion304
mechanism underlying FA release here is different to the traditional concept where305
drug release results from the direct dissolution of the carrier. This explains why the306
14
dissolution media were still cloudy even when virtually all the incorporated FA has307
been freed from the fibers.308
Fig. 6.309
4. Conclusions310
A modified coaxial electrospinning process has been developed for the311
preparation of ferulic acid (FA)-loaded shellac nanofibers, using a solvent mixture as312
the shell working fluid. This both helps to ensure a continuous electrospinning process313
can be implemented, and also can be used to manipulate the fiber diameters. Scanning314
electron microscopy demonstrated that linear fibers with smooth surfaces and315
cross-sections were obtained with shell-to-core fluid flow rate ratios of 0.1 and 0.25.316
FA was incorporated into the fibers in the amorphous physical form, as evidenced by317
X-ray diffraction and differential scanning calorimetry. IR spectra indicated the318
existence of hydrogen bonds between the shellac and FA. In vitro dissolution tests319
revealed that less than 10 % of the FA was released in a pH 2 solution, while the320
majority of the drug was freed over around 8 h in a neutral phosphate buffer. This321
suggests that the fibers may comprise a useful dosage forms for oral colon-targeted322
drug delivery. FA is freed from the fibers through an erosion-controlled mechanism,323
but this is more complex than a simple dissolution of the polymer to free the drug:324
prior to their dissolution the shellac molecules self-crimped into nanoparticles. The325
work reported herein comprises a potent strategy for the development of new326
nanofiber-based drug delivery systems from natural polymers.327
328
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Figures and table legends429
Fig. 1. A schematic illustrating the strategy underlying the design of the medicated430
shellac nanofibers prepared in this work.431
Fig. 2. Photographs of the electrospinning of FA-loaded shellac nanofibers using (a)432
single-fluid and (b) coaxial electrospinning. The inset in (a) shows clogging of the433
spinneret and that in (b) the Taylor cone observed during the coaxial process with434
shell and core fluid flow rates of 0.5 and 2 mL/h, respectively.435
Fig. 3. SEM images of the raw materials and nanofibers. (a) FA particles (photograph436
as inset); (b) a cross-section of a shellac sheet (photograph as inset); (c) F1; (d) F2; (e)437
F3; (f) F4; and, (g) the influence of shell-to-core fluid flow ratio on fiber diameter.438
The insets in (d) and (e) show the fiber cross-sections.439
Fig. 4. Physical form and component compatibility data. (a) XRD patterns; (b) DSC440
thermograms; (c) IR spectra; and, (d) the molecular structure of shellac.441
Fig. 5. The results of in vitro dissolution tests. The FA release profiles are given in (a),442
20
together with SEM images of F2 after (b) and (c) 3h; (d) and (e) 5h; and, (f) and (g)443
7h of dissolution444
Fig. 6. A schematic diagram of the proposed drug release mechanism.445
Table 1. Details of the electrospinning processes and resultant nanofibers.446
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